Press Releases

INCLINE VILLAGE, Nev. , March 13, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, May 28, 2014 , at 10:00 a.m. Pacific Time for all stockholders of record on April 4, 2014 .

INCLINE VILLAGE, Nev. , March 12, 2014 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 12, 2014, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 5, 2014, the record date.

INCLINE VILLAGE, Nev. , March 11, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the first quarter ending March 31, 2014, of approximately $133 million , as compared with actual revenue of $91.8 million for the first quarter of 2013, an

INCLINE VILLAGE, Nev. , March 10, 2014 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the appointment of David W. Gryska to its board of directors.  Mr. Gryska brings more than 30 years of strategic biopharmaceutical and financial leadership experience to PDL and has

INCLINE VILLAGE, Nev. , March 4, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 3.75% Convertible Senior Notes due May 1, 2015 ( May 2015 Notes), is 162.7280 shares of common stock per $1,000 principal amount or approximately

- Annual Revenues Increased 18 Percent during 2013 -

INCLINE VILLAGE, Nev. , Feb. 24, 2014 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year 2013 financial results for the period ended December 31, 2013 , on Monday, March 3, 2014 , after market close.

INCLINE VILLAGE, Nev. , Feb. 19, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the following upcoming conferences. (Logo:

INCLINE VILLAGE, Nev. and NEW YORK , Feb. 18, 2014 /PRNewswire/ --  PDL BioPharma, Inc. (NASDAQ: PDLI) and Paradigm Spine, LLC , a provider of innovative spinal implant technologies, announced today that the parties have entered into a credit agreement whereby PDL will provide Paradigm with up to

--Hoffman to Increase PDL's Expertise in Biotech/Pharma Sector--

INCLINE VILLAGE, Nev. , Feb. 12, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today the closing of its previously announced offering of convertible senior unsecured notes maturing on February 1, 2018 (2018 Notes).  PDL issued $300 million aggregate principal amount of

INCLINE VILLAGE, Nev. , Feb. 7, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has agreed to sell $260.87 million aggregate principal amount of its 4.00% Convertible Senior Notes due February 1, 2018 (the Notes) in an underwritten public offering.  The

INCLINE VILLAGE, Nev. , Feb. 7, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it entered into exchange and purchase agreements with certain holders of approximately $131.7 million aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015

INCLINE VILLAGE, Nev. , Feb. 5, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it intends to offer, subject to market and other conditions, $250 million aggregate principal amount of new convertible senior notes due February 1, 2018 (notes) under the Company's

INCLINE VILLAGE, Nev. , Feb. 4, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the BIO CEO and Investor Conference next week in New York City.  The presentation, which will